Press Releases 2025

Biocon Biologics  /  Press Releases  /  Press Releases 2025

Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement

  • Posted by: Biocon Biologics

Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM

  • Posted by: Biocon Biologics

Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide

  • Posted by: Biocon Biologics

S&P Global Places Biocon Biologics on Positive CreditWatch On Account of Accelerated Debt Reduction

  • Posted by: Biocon Biologics

Biocon Limited to Integrate Biocon Biologics Limited to Create a Unified Global Biopharmaceutical Leader

  • Posted by: Biocon Biologics

Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World

  • Posted by: Biocon Biologics

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20%

  • Posted by: Biocon Biologics

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

  • Posted by: Biocon Biologics

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

  • Posted by: Biocon Biologics

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: Biocon Biologics
Share